J Biomed Nanotechnol. 2020 Apr 1;16(4):432-445. doi: 10.1166/jbn.2020.2906.
Nanoparticle drug carriers trigger a variety of cellular stress responses, including ER stress and antioxidant responses, but may also affect the intracellular degradative pathway autophagy. This can impose profound effects on drug delivery, cellular treatment responses, and nanoparticle cytotoxicity. We recently demonstrated that even small variations in the alkyl side chains of poly(alkylcyanoacrylate) (PACA) drug carrier nanoparticles, namely butyl (PBCA), ethylbutyl (PEBCA), or octyl (POCA), differentially induce ER stress and redox imbalance in human cell lines. Here, we systematically investigate how these PACA variants affect autophagy. Interestingly, treatment with PEBCA or POCA particles led to intracellular accumulation of the autophagosome marker LC3-II, but via different mechanisms. PEBCA induced an integrated stress response-and ATF4-mediated increase in LC3B mRNA, whereas POCA blocked autophagic degradation of LC3-II and long-lived proteins in bulk. PBCA also increased mRNA via the integrated stress response and ATF4, but unlike PEBCA, it inhibited LC3 lipidation and autophagic cargo degradation. Our data demonstrate that even subtle variations in NP structure can have profoundly different impacts on autophagy, and that careful monitoring of autophagic flux and cargo degradation is critical for drawing accurate conclusions. Our findings have important implications for the choice of PACA monomer in different therapeutic settings.
纳米药物载体会引发多种细胞应激反应,包括内质网应激和抗氧化应激反应,但也可能影响细胞内的降解途径自噬。这会对药物传递、细胞治疗反应和纳米颗粒细胞毒性产生深远影响。我们最近证明,即使是聚(烷基氰基丙烯酸酯)(PACA)药物载体纳米颗粒的烷基侧链的微小变化,即丁基(PBCA)、乙基丁基(PEBCA)或辛基(POCA),也会在人细胞系中引起内质网应激和氧化还原失衡的差异。在这里,我们系统地研究了这些 PACA 变体如何影响自噬。有趣的是,PEBCA 或 POCA 颗粒的处理导致自噬体标记物 LC3-II 的细胞内积累,但通过不同的机制。PEBCA 诱导了整合应激反应和 ATF4 介导的 LC3B mRNA 增加,而 POCA 则阻止了 LC3-II 和大量长寿命蛋白的自噬降解。PBCA 也通过整合应激反应和 ATF4 增加了 mRNA,但与 PEBCA 不同,它抑制了 LC3 脂质化和自噬货物降解。我们的数据表明,即使 NP 结构的微小变化也会对自噬产生深远的影响,并且仔细监测自噬通量和货物降解对于得出准确的结论至关重要。我们的发现对于在不同治疗环境中选择 PACA 单体具有重要意义。